Philips Initiates Class I Recall of Tack Endovascular System Due to Safety Concerns

Key Insights

• Philips has recalled its Tack Endovascular System following 20 reported injuries, with the FDA classifying it as a Class I recall due to serious safety concerns.
• The recall affects approximately 3,000 units globally, with potential complications including arterial occlusion, dissection, perforation, and risks of amputation or death.
• Healthcare providers are instructed to immediately cease using all three sizes of the device, with Philips implementing a complete market withdrawal and return process.

Philips has initiated an immediate market withdrawal of its Tack Endovascular System following significant safety concerns that prompted the U.S. Food and Drug Administration (FDA) to issue a Class I recall. The company has received 20 reports of injuries associated with the device, which is designed for treating peripheral arterial dissections following balloon angioplasty procedures.

Safety Concerns and Clinical Implications

The FDA advisory highlights several serious risks associated with the affected devices, including both immediate and long-term complications. Immediate risks include partial or complete blood flow blockage, arterial dissection, and vessel wall perforation. Long-term complications may encompass chronic pain, tissue loss, restenosis, and in severe cases, the need for bypass surgery, amputation, or potential death.

Scope and Impact of Recall

The recall encompasses all three sizes of the Tack Endovascular System, affecting approximately 3,000 units globally, with 246 units distributed in the United States. A Philips spokesperson stated, "Philips has become aware of challenges customers may have experienced with affected systems, and reports of instances where additional clinical intervention was required during device use."

Immediate Actions Required

Healthcare providers are instructed to:

• Immediately discontinue use of all affected devices
• Quarantine any remaining inventory
• Complete and return the required response form for product returns and credits
• Report any adverse events or quality problems to the FDA

While the situation is serious enough to warrant a Class I recall - the FDA's most severe classification - Philips has emphasized that they are currently unaware of any patient deaths associated with the device's use. However, the company has confirmed it will no longer distribute the Tack Endovascular System and is working with healthcare facilities to ensure proper device removal from circulation.

Clinical Management Considerations

Interventional cardiologists and vascular specialists who have previously used the Tack Endovascular System will need to evaluate alternative treatment options for patients requiring peripheral arterial dissection management. The immediate cessation of device use may impact treatment planning for scheduled procedures, necessitating careful consideration of available alternatives.